146 related articles for article (PubMed ID: 11118091)
1. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation.
Legendre CM; Norman DJ; Keating MR; Maclaine GD; Grant DM
Transplantation; 2000 Nov; 70(10):1463-8. PubMed ID: 11118091
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
Mauskopf JA; Richter A; Annemans L; Maclaine G
Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391
[TBL] [Abstract][Full Text] [Related]
3. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation.
Tilden DP; Chapman J; Davey PJ; Solly ML; Crowley S
Clin Transplant; 2004 Jun; 18(3):312-20. PubMed ID: 15142054
[TBL] [Abstract][Full Text] [Related]
4. The economic value of valacyclovir prophylaxis in transplantation.
Squifflet JP; Legendre C
J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of lowering immunosuppression to treat CMV infection in renal transplant recipients on valaciclovir prophylaxis: a pilot study.
Anglicheau D; Lautrette A; Scieux C; Flamant M; Morinet F; Legendre C
Nephrol Dial Transplant; 2003 Aug; 18(8):1654-6. PubMed ID: 12897109
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
Feinberg JE; Hurwitz S; Cooper D; Sattler FR; MacGregor RR; Powderly W; Holland GN; Griffiths PD; Pollard RB; Youle M; Gill MJ; Holland FJ; Power ME; Owens S; Coakley D; Fry J; Jacobson MA
J Infect Dis; 1998 Jan; 177(1):48-56. PubMed ID: 9419169
[TBL] [Abstract][Full Text] [Related]
7. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
Reddy SP; Handa A; Tan L; Devaney A; Hughes D; Mason P; Friend PJ; Darby CR
Transpl Int; 2003 Oct; 16(10):726-9. PubMed ID: 12827230
[TBL] [Abstract][Full Text] [Related]
8. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation.
Legendre C; Beard SM; Crochard A; Lebranchu Y; Pouteil-Noble C; Richter A; Durand-Zaleski I
Eur J Health Econ; 2005 Jun; 6(2):172-82. PubMed ID: 15765243
[TBL] [Abstract][Full Text] [Related]
10. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Ladhani M; Webster AC; Strippoli GF; Craig JC
Cochrane Database Syst Rev; 2013 Feb; (2):CD003774. PubMed ID: 23450543
[TBL] [Abstract][Full Text] [Related]
11. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
Reischig T; Jindra P; Hes O; Svecová M; Klaboch J; Treska V
Am J Transplant; 2008 Jan; 8(1):69-77. PubMed ID: 17973956
[TBL] [Abstract][Full Text] [Related]
12. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
13. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients.
Toussaint ND; Tan MB; Nicholls K; Walker RG; Cohney SJ
Nephrology (Carlton); 2011 Jan; 16(1):113-7. PubMed ID: 21175987
[TBL] [Abstract][Full Text] [Related]
14. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
Ormrod D; Scott LJ; Perry CM
Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
[TBL] [Abstract][Full Text] [Related]
15. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial.
Egan JJ; Carroll KB; Yonan N; Woodcock A; Crisp A
J Heart Lung Transplant; 2002 Apr; 21(4):460-6. PubMed ID: 11927223
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation.
Reischig T; Kacer M
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):771-9. PubMed ID: 25252996
[TBL] [Abstract][Full Text] [Related]
17. Lowering immunosuppression is safe and effective to treat altered pattern of CMV infection in renal transplant recipients on valaciclovir prophylaxis.
Anglicheau D; Lautrette A; Scieux C; Thervet E; Martinez F; Flamant M; Morinet F; Legendre C
Transplant Proc; 2002 Nov; 34(7):2826-7. PubMed ID: 12431624
[No Abstract] [Full Text] [Related]
18. CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valaciclovir.
Sund F; Wahlberg J; Eriksson BM
J Clin Virol; 2001 Dec; 23(1-2):107-11. PubMed ID: 11595589
[TBL] [Abstract][Full Text] [Related]
19. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.
Reischig T; Jindra P; Mares J; Cechura M; Svecová M; Hes O; Opatrný K; Treska V
Transplantation; 2005 Feb; 79(3):317-24. PubMed ID: 15699762
[TBL] [Abstract][Full Text] [Related]
20. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
Kacer M; Kielberger L; Bouda M; Reischig T
Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
